NovoCure Limited

NasdaqGS:NVCR Stock Report

Market Cap: US$3.3b

NovoCure Management

Management criteria checks 4/4

NovoCure's CEO is Asaf Danziger, appointed in Jan 2002, has a tenure of 22.92 years. total yearly compensation is $1.52M, comprised of 49.7% salary and 50.3% bonuses, including company stock and options. directly owns 0.014% of the company’s shares, worth $468.90K. The average tenure of the management team and the board of directors is 2.7 years and 7.1 years respectively.

Key information

Asaf Danziger

Chief executive officer

US$1.5m

Total compensation

CEO salary percentage49.7%
CEO tenure22.9yrs
CEO ownership0.01%
Management average tenure2.7yrs
Board average tenure7.1yrs

Recent management updates

Recent updates

NovoCure Limited (NASDAQ:NVCR) Looks Just Right With A 84% Price Jump

Dec 03
NovoCure Limited (NASDAQ:NVCR) Looks Just Right With A 84% Price Jump

Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFields

Dec 02

Analyst Estimates: Here's What Brokers Think Of NovoCure Limited (NASDAQ:NVCR) After Its Third-Quarter Report

Nov 01
Analyst Estimates: Here's What Brokers Think Of NovoCure Limited (NASDAQ:NVCR) After Its Third-Quarter Report

Is NovoCure (NASDAQ:NVCR) A Risky Investment?

Oct 17
Is NovoCure (NASDAQ:NVCR) A Risky Investment?

NovoCure: There Is Still More Upside

Oct 16

NovoCure's Stock Stagnates Amid Lack Of Progress Beyond GBM

Oct 09

Investors Appear Satisfied With NovoCure Limited's (NASDAQ:NVCR) Prospects

Sep 12
Investors Appear Satisfied With NovoCure Limited's (NASDAQ:NVCR) Prospects

NovoCure Limited: A Post Q2 Analysis

Jul 26

NovoCure Limited Q1 Earnings: Core Business Accelerating

May 03

NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?

Apr 08
NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?

NovoCure: Sell The METIS-Inspired Rally

Mar 28

Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio

Mar 03
Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio

NovoCure: Stay Cautious Amid Positive Signs

Jan 19

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Nov 16
Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?

Aug 13
Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?

Is NovoCure (NASDAQ:NVCR) A Risky Investment?

May 15
Is NovoCure (NASDAQ:NVCR) A Risky Investment?

A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)

Apr 24
A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)

Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching

Feb 10
Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Jan 16
Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

CEO Compensation Analysis

How has Asaf Danziger's remuneration changed compared to NovoCure's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$150m

Jun 30 2024n/an/a

-US$169m

Mar 31 2024n/an/a

-US$193m

Dec 31 2023US$2mUS$756k

-US$207m

Sep 30 2023n/an/a

-US$197m

Jun 30 2023n/an/a

-US$174m

Mar 31 2023n/an/a

-US$141m

Dec 31 2022US$2mUS$831k

-US$93m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022n/an/a

-US$68m

Mar 31 2022n/an/a

-US$59m

Dec 31 2021US$1mUS$876k

-US$58m

Sep 30 2021n/an/a

-US$27m

Jun 30 2021n/an/a

-US$5m

Mar 31 2021n/an/a

US$12m

Dec 31 2020US$9mUS$782k

US$20m

Sep 30 2020n/an/a

US$19m

Jun 30 2020n/an/a

US$12m

Mar 31 2020n/an/a

US$9m

Dec 31 2019US$7mUS$702k

-US$7m

Sep 30 2019n/an/a

-US$27m

Jun 30 2019n/an/a

-US$41m

Mar 31 2019n/an/a

-US$55m

Dec 31 2018US$5mUS$693k

-US$64m

Sep 30 2018n/an/a

-US$59m

Jun 30 2018n/an/a

-US$59m

Mar 31 2018n/an/a

-US$64m

Dec 31 2017US$4mUS$698k

-US$62m

Compensation vs Market: Asaf's total compensation ($USD1.52M) is below average for companies of similar size in the US market ($USD6.65M).

Compensation vs Earnings: Asaf's compensation has been consistent with company performance over the past year.

CEO

Asaf Danziger (58 yo)

22.9yrs

Tenure

US$1,521,026

Compensation

Mr. Asaf Danziger is a Director at Airway Therapeutics, Inc. since April 2020. He has been the Chief Executive Officer of Novocure Limited since 2002 and its Director since 2012 respectively and also serve...

Leadership Team

NamePositionTenureCompensationOwnership
William Doyle
Executive Chairman20.9yrsUS$1.43m0.51%
$ 17.0m
Asaf Danziger
CEO & Director22.9yrsUS$1.52m0.014%
$ 468.9k
Ashley Cordova
Chief Financial Officer4.3yrsUS$6.32m0.085%
$ 2.8m
Barak Arye
General Counsel2.7yrsUS$4.86m0.019%
$ 648.5k
Frank Leonard
Executive VP & President of Novocure Oncology4.3yrsUS$5.04m0.055%
$ 1.8m
Yoram Palti
Founder & CTO24.9yrsUS$282.51kno data
Mukund Paravasthu
Chief Operating Officerless than a yearno data0.0032%
$ 106.6k
Ingrid Goldberg
VP of Investor Relationsno datano datano data
Michael Puri
Chief Human Resources Officer1.3yrsno data0.012%
$ 414.6k
Uri Weinberg
Chief Innovation Officer1.9yrsno data0.057%
$ 1.9m
Piet Hinoul
Senior VPno datano datano data
Nicolas Leupin
Chief Medical Officerless than a yearno datano data

2.7yrs

Average Tenure

53yo

Average Age

Experienced Management: NVCR's management team is considered experienced (2.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
William Doyle
Executive Chairman20.9yrsUS$1.43m0.51%
$ 17.0m
Asaf Danziger
CEO & Director12.9yrsUS$1.52m0.014%
$ 468.9k
Jeryl Hilleman
Independent Director6.4yrsUS$446.09k0.0023%
$ 78.0k
David Hung
Independent Director6.6yrsUS$426.09k0.0084%
$ 281.6k
Timothy Scannell
Independent Director3.8yrsUS$448.53k0.0036%
$ 121.0k
Kinyip Leung
Independent Director13.2yrsUS$435.53k0.073%
$ 2.4m
William Vernon
Lead Independent Director18.9yrsUS$475.53k0.15%
$ 5.0m
Martin Madden
Independent Director7.6yrsUS$446.09k0.014%
$ 481.2k
Kristin Stafford
Independent Director1.8yrsUS$696.94k0%
$ 0
Allyson Ocean
Independent Director1.8yrsUS$697.26k0%
$ 0

7.1yrs

Average Tenure

62yo

Average Age

Experienced Board: NVCR's board of directors are considered experienced (7.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 05:12
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NovoCure Limited is covered by 15 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Difei YangAegis Capital Corporation
Gregory GilbertDeutsche Bank
Vijay KumarEvercore ISI